 University at Buffalo Reporter | Health and wellness in the community is the theme of this year's UBThisSummer ... University at Buffalo Reporter July 11: “Nanomedicine: Transforming Health Care with Nanotechnology,” Paras Prasad, SUNY Distinguished Professor and executive director, Institute for Lasers, Photonics and Biophotonics. Prasad will discuss the emerging field of nanomedicine—and UB's ... |
NanoViricides Appoints Mr. Andrew Hahn as Consultant for Design and ... EON: Enhanced Online News (press release) “This will be a unique, state-of-the-art cGMP facility for the pilot scale production of nanomedicines,” said Anil R. Diwan, President and Chairman of the Company, adding, “Along with his great experience, Andy Hahn brings an acute grasp of a wide ... |
 Science Business | New Summer Research School in nanomedicine at Karolinska Science Business This summer, the Swedish medical university Karolinska Institutet will be launching a summer research school in nanomedicine together with Peking University and Japan's RIKEN Brain Science Institute and Keio University. Research students will be ... |
Arrowhead Reports Fiscal 2012 Second Quarter Financial Results TheStreet.com (press release) By Business Wire 05/08/12 - 04:01 PM EDT Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended March ... |
Arrowhead Reports Fiscal 2012 Second Quarter Financial Results MarketWatch (press release) PASADENA, Calif., May 08, 2012 (BUSINESS WIRE) -- Arrowhead Research Corporation (UTD:ARWR) , a nanomedicine company with development programs in RNA therapeutics and obesity, today announced financial results for its fiscal 2012 second quarter ended ... |
NanoViricides Announces Issuance of a Fundamental Patent in the USA EON: Enhanced Online News (press release) The disclosed structures enable self-assembling, biomimetic nanomedicines. NanoViricides, Inc. holds exclusive, perpetual, worldwide licenses to these technologies for a broad range of antiviral applications and diseases. Based on international PCT ... |
MagForce to Present at Entry & General Standard Conference 2012 in Frankfurt Reuters Berlin, Germany, May 07, 2012 - MagForce AG (Frankfurt, XETRA: MF6), a leading medical technology company in the field of nanomedicine for oncology, announced today that Dr Andreas Jordan, Executive Board, will deliver a presentation on the Company at ... |
Midatech and MonoSol Rx Announce Positive Phase 1 Clinical Results for Their ... MarketWatch (press release) Top-line results, including PK and bioavailability elements, from the study will be presented at the European Summit for Clinical Nanomedicine (CLINAM) in Basel, Switzerland by Prof.Dr. med. Fritz R. Buhler, Chief Medical Officer and member of the ... |
Cooperative dual-activity targeted nanomedicine for specific and effective ... UroToday In this study, we developed a cooperative dual-targeted delivery platform for paclitaxel (PTX) that has potential application as a powerful prostate cancer treatment. The nanomedicine was prepared by first conjugating PTX to nontoxic high-magnetization ... |
Nanotechnology and Medicine dailyRx The concept behind nanomedicine is fairly simple. Any drug given to a person has to have certain chemical characteristics, otherwise it won't go anywhere. If a drug is given orally, it has to have suitable properties in order to be taken either with, ... |